TCG Crossover Management Portfolio
Growth & qualityTCG Crossover Management, LLC 13F holdings · Q3 2026 vs Q2 2026
Why growth & quality: 54 holdings, 16 effective · top 10 57% · turnover 17% a quarter · earnings yield -10.8% (median 2.9%) · 20 quarters of 13Fs
- 13F value
- $3.5bn−14.9% vs $4.2bn in Q2 2026
- Holdings
- 49 5 new · 4 sold out
- Top 10 weight
- 53.3% Largest: ABVX 10.2%
- Bought est.
- $311m New positions and adds
- Sold est.
- $611m Trims and exits
- Quarter
- Q3 2026 Filed
Largest trades since Q2 2026
Estimated dollars: the change in shares times the quarter-end price the filing implies. Exits use last quarter's value.
| Action | Stock | Shares | Est. traded | Weight | Other gurus |
|---|---|---|---|---|---|
| Trimmed | ABVXABIVAX SA AMERICAN DEPOSITARY SHARES | −39.0% | −$232m | 19.2% → 10.2% | 6 |
| New | KRSAKORSANA BIOSCIENCES INC | New | +$146m | 0.0% → 4.1% | 5 |
| New | ADRXADARX PHARMACEUTICALS INC | New | +$82m | 0.0% → 2.3% | 2 |
| Trimmed | COGTCOGENT BIOSCIENCES INC | −48.5% | −$75m | 4.5% → 2.3% | 7 |
| Sold out | RVMDREVOLUTION MEDICINES INC | −100.0% | −$64m | 1.5% → 0.0% | — |
| Trimmed | TNGXTANGO THERAPEUTICS INC | −25.4% | −$58m | 6.8% → 4.8% | 7 |
| Sold out | SRZNSURROZEN INC | −100.0% | −$38m | 0.9% → 0.0% | — |
| New | TARSTARSUS PHARMACEUTICALS INC | New | +$31m | 0.0% → 0.9% | 3 |
| Sold out | ALTALTIMMUNE INC | −100.0% | −$30m | 0.7% → 0.0% | — |
| New | OBXOBSIDIAN THERAPEUTICS INC | New | +$30m | 0.0% → 0.9% | 4 |
| Trimmed | LBRXLB PHARMACEUTICALS INC | −47.1% | −$26m | 1.1% → 0.8% | 3 |
| Sold out | FBRXGBPFORTE BIOSCIENCES INC | −100.0% | −$20m | 0.5% → 0.0% | — |
| Trimmed | SLNSILENCE THERAPEUTICS PLC | −40.0% | −$13m | 0.8% → 0.6% | 3 |
| Trimmed | AKTSAKTIS ONCOLOGY INC | −80.8% | −$11m | 0.5% → 0.1% | 3 |
| Trimmed | GLUEMONTE ROSA THERAPEUTICS INC | −18.2% | −$10m | 2.7% → 1.3% | 4 |
| Trimmed | XNCRXENCOR INC | −16.2% | −$9.9m | 0.9% → 1.4% | 4 |
| Trimmed | RLAYRELAY THERAPEUTICS INC | −11.5% | −$8.8m | 1.9% → 1.9% | 3 |
| Trimmed | OCULOCULAR THERAPEUTIX INC | −56.3% | −$7.1m | 0.4% → 0.2% | 2 |
| New | AGENAGENUS INC | New | +$6.0m | 0.0% → 0.2% | 1 |
| Added | TYRATYRA BIOSCIENCES INC | +7.0% | +$5.0m | 2.5% → 2.1% | 5 |
| Added | MIRMMIRUM PHARMACEUTICALS INC | +5.4% | +$4.9m | 3.0% → 2.7% | 8 |
| Trimmed | ALXOALX ONCOLOGY HOLDINGS INC | −56.4% | −$4.4m | 0.3% → 0.1% | 1 |
| Added | AURAAURA BIOSCIENCES INC | +6.6% | +$4.0m | 1.6% → 1.8% | 3 |
| Trimmed | AGMBAGOMAB THERAPEUTICS NV | −11.3% | −$2.6m | 0.6% → 0.6% | 1 |
| Added | ZLABZAI LAB LTD-ADR | +1.5% | +$2.4m | 2.8% → 4.6% | 4 |
| Trimmed | MNPRMONOPAR THERAPEUTICS INC | −0.5% | −$86k | 0.5% → 0.5% | 2 |
All holdings 49 identified, plus $130m in securities without a listed ticker
Click a column to sort. Values are as reported at quarter-end, not today's prices.
| # | Stock | Shares | ||||
|---|---|---|---|---|---|---|
| 1 | ABVXABIVAX SA AMERICAN DEPOSITARY SHARES | $363m | 3,663,038 | −39.0% | 6 | |
| 2 | CGONCG ONCOLOGY INC | $260m | 3,670,206 | Unchanged | 1 | |
| 3 | AMLXAMYLYX PHARMACEUTICALS INC | $182m | 6,243,812 | Unchanged | 2 | |
| 4 | SYRESPYRE THERAPEUTICS INC | $169m | 1,900,582 | Unchanged | 3 | |
| 5 | TNGXTANGO THERAPEUTICS INC | $169m | 6,773,043 | −25.4% | 7 | |
| 6 | ZLABZAI LAB LTD-ADR | $164m | 6,229,081 | +1.5% | 4 | |
| 7 | IMVTIMMUNOVANT INC | $151m | 4,457,988 | Unchanged | 5 | |
| 8 | DNTHDIANTHUS THERAPEUTICS INC | $148m | 1,676,624 | Unchanged | 5 | |
| 9 | KRSAKORSANA BIOSCIENCES INC | $146m | 4,549,587 | New | 5 | |
| 10 | KODKODIAK SCIENCES INC | $137m | 1,445,538 | Unchanged | 3 | |
| 11 | VORVOR BIOPHARMA INC | $108m | 5,673,078 | Unchanged | 4 | |
| 12 | TRAXFIRST TRACKS BIOTHERAPEUTICS | $103m | 2,895,304 | Unchanged | 1 | |
| 13 | MIRMMIRUM PHARMACEUTICALS INC | $96m | 1,118,967 | +5.4% | 8 | |
| 14 | BCRXBIOCRYST PHARMACEUTICALS INC | $92m | 11,020,968 | Unchanged | 4 | |
| 15 | IRONDISC MEDICINE INC | $88m | 1,341,862 | Unchanged | 6 | |
| 16 | ADRXADARX PHARMACEUTICALS INC | $82m | 4,116,452 | New | 2 | |
| 17 | COGTCOGENT BIOSCIENCES INC | $80m | 2,500,003 | −48.5% | 7 | |
| 18 | TYRATYRA BIOSCIENCES INC | $76m | 3,475,980 | +7.0% | 5 | |
| 19 | DYNDYNE THERAPEUTICS INC | $74m | 4,615,144 | Unchanged | 5 | |
| 20 | RLAYRELAY THERAPEUTICS INC | $68m | 3,783,529 | −11.5% | 3 | |
| 21 | AURAAURA BIOSCIENCES INC | $64m | 10,165,357 | +6.6% | 3 | |
| 22 | SVRASAVARA INC | $64m | 12,362,205 | Unchanged | 4 | |
| 23 | XNCRXENCOR INC | $51m | 2,055,938 | −16.2% | 4 | |
| 24 | AVTXAVALO THERAPEUTICS INC | $46m | 3,017,120 | Unchanged | 5 | |
| 25 | GLUEMONTE ROSA THERAPEUTICS INC | $45m | 3,781,532 | −18.2% | 4 | |
| 26 | MBXMBX BIOSCIENCES INC | $38m | 650,000 | Unchanged | 3 | |
| 27 | JANXJANUX THERAPEUTICS INC | $31m | 1,789,617 | Unchanged | 2 | |
| 28 | TARSTARSUS PHARMACEUTICALS INC | $31m | 388,164 | New | 3 | |
| 29 | IPSCCENTURY THERAPEUTICS INC | $30m | 17,754,430 | Unchanged | 2 | |
| 30 | OBXOBSIDIAN THERAPEUTICS INC | $30m | 2,196,138 | New | 4 | |
| 31 | LBRXLB PHARMACEUTICALS INC | $29m | 765,050 | −47.1% | 3 | |
| 32 | EDITEDITAS MEDICINE INC | $29m | 11,111,111 | Unchanged | 2 | |
| 33 | TECXTECTONIC THERAPEUTIC INC | $28m | 1,204,891 | Unchanged | 1 | |
| 34 | CATXPERSPECTIVE THERAPEUTICS INC | $22m | 7,915,567 | Unchanged | — | |
| 35 | AGMBAGOMAB THERAPEUTICS NV | $20m | 1,820,831 | −11.3% | 1 | |
| 36 | SLNSILENCE THERAPEUTICS PLC | $20m | 1,819,035 | −40.0% | 3 | |
| 37 | ALECALECTOR INC | $19m | 10,000,000 | Unchanged | 3 | |
| 38 | MNPRMONOPAR THERAPEUTICS INC | $16m | 202,242 | −0.5% | 2 | |
| 39 | TRDAENTRADA THERAPEUTICS INC | $6.7m | 1,060,230 | Unchanged | 2 | |
| 40 | CGEMCULLINAN THERAPEUTICS INC | $6.2m | 406,786 | Unchanged | 3 | |
| 41 | AGENAGENUS INC | $6.0m | 603,892 | New | 1 | |
| 42 | OCULOCULAR THERAPEUTIX INC | $5.5m | 720,323 | −56.3% | 2 | |
| 43 | ARVNARVINAS INC | $5.5m | 707,098 | Unchanged | 1 | |
| 44 | KRROKORRO BIO INC | $4.1m | 416,301 | Unchanged | — | |
| 45 | ALXOALX ONCOLOGY HOLDINGS INC | $3.4m | 2,465,436 | −56.4% | 1 | |
| 46 | AKTSAKTIS ONCOLOGY INC | $2.6m | 133,457 | −80.8% | 3 | |
| 47 | LONALEONABIO INC | $1.7m | 464,398 | Unchanged | 1 | |
| 48 | CNTXCONTEXT THERAPEUTICS INC | $806k | 2,682,696 | Unchanged | 1 | |
| 49 | EIKNEIKON THERAPEUTICS INC | $305k | 37,902 | Unchanged | 1 |
Closest portfolios
Overlap is the weight two books have in common: for each shared stock, the smaller of the two weights, summed.
- Rtw Investments22.7%21 shared · CGON, TNGX, SYRE, ZLAB
- Perceptive Advisors16.0%12 shared · AMLX, SYRE, RLAY, BCRX
- Paradigm Biocapital Advisors13.7%9 shared · SYRE, TNGX, TYRA, MBX
- Ra Capital Management13.5%19 shared · TYRA, IRON, XNCR, AMLX
- Frazier Life Sciences Management13.1%12 shared · MIRM, DYN, IRON, VOR
- Fairmount Funds Management10.5%3 shared · DNTH, KRSA, COGT
- Deerfield Management9.7%10 shared · COGT, TNGX, BCRX, DNTH
- Bvf7.7%8 shared · TYRA, XNCR, GLUE, MIRM
- Baker Bros. Advisors6.1%18 shared · KOD, IMVT, DNTH, GLUE
- Novo Holdings5.0%3 shared · MIRM, DYN, OBX
Only here
The largest holdings no other tracked guru owns.
- CATXPERSPECTIVE THERAPEUTICS INC0.6%
- KRROKORRO BIO INC0.1%
A 13F is a filing, not a live portfolio. It lists US-listed long stock positions at quarter-end, and it arrives up to 45 days later. Cash, shorts, bonds, options and foreign listings are not in it. Trade sizes here are estimates from the change in share count, restated for stock splits.
Snapshot refreshed